Crenigacestat

Drug Profile

Crenigacestat

Alternative Names: LY-3039478

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Benzazepines; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Lymphoma
  • Phase I Cancer; Solid tumours
  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 06 Dec 2017 Crenigacestat licensed to Juno Therapeutics as a combination therapy for the treatment of multiple myeloma
  • 06 Dec 2017 Juno Therapeutics plans a clinical trial for Multiple myeloma (Combination therapy) in 2018
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease) in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top